×
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
NASDAQ:MRNA

Moderna Stock Forecast, Price & News

$155.54
+5.59 (+3.73%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$146.84
$158.79
50-Day Range
$117.13
$155.54
52-Week Range
$115.61
$497.49
Volume
6.01 million shs
Average Volume
5.06 million shs
Market Capitalization
$61.87 billion
P/E Ratio
4.57
Dividend Yield
N/A
Price Target
$228.00

Moderna MarketRank™ Forecast

Analyst Rating
Hold
2.23 Rating Score
Upside/​Downside
46.6% Upside
$228.00 Price Target
Short Interest
Healthy
4.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.71
Upright™ Environmental Score
News Sentiment
0.22mentions of Moderna in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$57.45 M Sold Last Quarter
Proj. Earnings Growth
-71.62%
From $27.27 to $7.74 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.41 out of 5 stars

Medical Sector

139th out of 1,426 stocks

Biological Products, Except Diagnostic Industry

19th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Moderna logo

About Moderna (NASDAQ:MRNA) Stock

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

MRNA Stock News Headlines

Brokerages Set Moderna, Inc. (NASDAQ:MRNA) PT at $228.00
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
2,700
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/06/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$228.00
High Stock Price Forecast
$395.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+46.6%
Consensus Rating
Hold
Rating Score (0-4)
2.23076923076923
Research Coverage
13 Analysts

Profitability

Net Income
$12.20 billion
Pretax Margin
71.92%

Debt

Sales & Book Value

Annual Sales
$18.47 billion
Cash Flow
$31.94 per share
Book Value
$34.89 per share

Miscellaneous

Free Float
328,948,000
Market Cap
$61.87 billion
Optionable
Optionable
Beta
1.65

Social Links















Moderna Frequently Asked Questions

Should I buy or sell Moderna stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 1 sell rating, 8 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Moderna stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Moderna
or view top-rated stocks.

What is Moderna's stock price forecast for 2022?

13 brokers have issued 12-month target prices for Moderna's stock. Their MRNA stock forecasts range from $70.00 to $395.00. On average, they expect Moderna's share price to reach $228.00 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price.
View analysts' price targets for Moderna
or view top-rated stocks among Wall Street analysts.

How has Moderna's stock price performed in 2022?

Moderna's stock was trading at $253.98 at the beginning of the year. Since then, MRNA stock has decreased by 38.8% and is now trading at $155.54.
View the best growth stocks for 2022 here
.

When is Moderna's next earnings date?

Moderna is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Moderna
.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its quarterly earnings results on Wednesday, May, 4th. The company reported $8.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.18 by $3.40. The firm had revenue of $6.07 billion for the quarter, compared to analyst estimates of $4.43 billion. Moderna had a trailing twelve-month return on equity of 121.86% and a net margin of 64.77%. Moderna's revenue was up 213.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 EPS.
View Moderna's earnings history
.

Who are Moderna's key executives?

Moderna's management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board (Age 59, Pay $1.12M)
  • Mr. Stephane Bancel, CEO & Director (Age 49, Pay $3.16M)
  • Dr. Stephen Hoge M.D., Pres (Age 46, Pay $1.8M)
  • Mr. David W. Meline, Chief Financial Officer (Age 65, Pay $1.24M) (LinkedIn Profile)
  • Ms. Shannon Thyme Klinger, Chief Legal Officer & Corp. Sec. (Age 51, Pay $1.76M) (LinkedIn Profile)
  • Mr. Juan Andres, Chief Technical Operations & Quality Officer (Age 57, Pay $1.6M) (LinkedIn Profile)
  • Dr. John V. W. Reynders Ph.D., Chief Information Officer
  • Dr. Melissa J. Moore Ph.D., Chief Scientific Officer & Member of Scientific Advisory Board
  • Ms. Lavina Talukdar CFA, Sr. VP & Head of Investor Relations
  • Colleen Hussey, Sr. Director of Corp. Communications

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna CEO Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among Moderna's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Who are Moderna's major shareholders?

Moderna's stock is owned by many different institutional and retail investors. Top institutional shareholders include Modus Advisors LLC (0.00%). Company insiders that own Moderna stock include David W Meline, Dustin A Moskovitz, Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Peter Barton Hutt, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, Ventures Fund Iv Gene Flagship and W Don Cornwell.
View institutional ownership trends for Moderna
.

Which major investors are buying Moderna stock?

MRNA stock was purchased by a variety of institutional investors in the last quarter, including Modus Advisors LLC. Company insiders that have bought Moderna stock in the last two years include Dustin A Moskovitz, Juan Andres, and W Don Cornwell.
View insider buying and selling activity for Moderna
or or view top insider-buying stocks.

How do I buy shares of Moderna?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $155.54.

How much money does Moderna make?

Moderna (NASDAQ:MRNA) has a market capitalization of $61.87 billion and generates $18.47 billion in revenue each year. The company earns $12.20 billion in net income (profit) each year or $34.03 on an earnings per share basis.

How many employees does Moderna have?

Moderna employs 2,700 workers across the globe.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for Moderna is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.

This page (NASDAQ:MRNA) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.